HIV Guidelines

HIV Treatment and Management

HIV Testing and Prevention

HIV Guidelines

New rapid guidance: Six-month oral PrEP prescribing

Medical and nurse practitioners can now prescribe up to a six-month supply of oral PrEP in the form of tenofovir disoproxil + emtricitabine on a single prescription following changes to the PBS. Read the rapid guidance here.

References

  1. Australasian Sexual Health Alliance (ASHA). Australian STI management guidelines for use in primary care
    [internet]. Taking a sexual history and contact tracing. Updated December 2018. Available at: http://www.sti.guidelines.org.au/resources/how-to-take-a-sexual-history#how-to-take-a-sexual-history (last
    accessed 3 September 2019).
  2. Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. Transgender women in
    clinical
    trials of pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2016;72 Suppl 3:S226-9.
  3. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention
    in men
    who have sex with men. N Engl J Med 2010;363:2587-99.
  4. Mehrotra ML, Westreich D, McMahan VM, et al. Baseline characteristics explain differences in
    effectiveness of
    randomization to daily oral TDF/FTC PrEP between transgender women and cisgender men who have sex with men in
    the iPrEx Trial. J Acquir Immune Defic Syndr 2019; 81:e94-8
  5. Centers for Disease Control and Prevention (CDC). Integrated prevention services for HIV infection, viral
    hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance
    from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep 2012;61(RR-5):1–40.
  6. International Network of People who Use Drugs (INPUD). Position paper: pre-exposure prophylaxis (PrEP)
    for
    people who inject drugs. April 2015. Available at: www.inpud.net/INPUD_PositionPaper_Pre-exposure_prophylaxis_PrEP_April15.pdf (last
    accessed 3 September 2019).
  7. Wodak A, Maher L. The effectiveness of harm reduction in preventing HIV among injecting drug users. NSW
    Public
    Health Bulletin 2010;21(3–4):69-73.
  8. Kwon JA, Iversen J, Law M, Dolan K, Wand H, Maher L. Estimating the number of people who inject drugs and
    syringe coverage in Australia, 2005-2016. Drug Alcohol Depend 2019;197:108-14.
  9. Bazzi AR, Drainoni ML, Biancarelli DL, et al. Systematic review of HIV treatment adherence research among
    people
    who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence
    interventions. BMC Public Health 2019;19:31.
  10. Biello KB, Bazzi AR, Mimiaga MJ, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization
    and
    related intervention needs among people who inject drugs. Harm Reduct J 2018;15:55.
HIV Guidelines

HIV Treatment and Management

HIV Testing and Prevention

Frequently used tools